Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855304 | 0.94 | POLB (0.38) | PARP1LMNASMN1; SMN2MMP2MMP9 | |
| SCHEMBL1815845 | 0.87 | MAOA (0.35) | ACACBLMNASMN1; SMN2MMP2MMP9 | |
| SCHEMBL1813904 | 0.81 | POLB (0.41) | LMNASMN1; SMN2MMP2MMP9TDP1 | |
| Hydrochloric Acid SCHEMBL2858475 | 0.80 | POLB (0.40) | LMNASMN1; SMN2MMP2MMP9TDP1 | |
| SCHEMBL1815941 | 0.77 | CYP1A2 (0.46) | LMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL13708340 | 0.76 | LTB4R2 (0.38) | POLBFFAR1 | |
| SCHEMBL1814184 | 0.75 | PTPN11 (0.52) | TDP1L3MBTL1FFAR1 | |
| SCHEMBL1815305 | 0.75 | ALDH1A1 (0.40) | LMNASMN1; SMN2FFAR1 | |
| SCHEMBL1813337 | 0.74 | POLB (0.41) | LMNASMN1; SMN2MMP2MMP9TDP1 | |
| SCHEMBL4456870 | 0.74 | PTPN11 (0.42) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | ACACB 105/4885PARP1 2638/4885LMNA 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.